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Psoriasis, a common skin disorder, is widely
regarded to be multifactorial in origin including
gene±gene and gene±environment interactions.
Genetic and allelic heterogeneity, multifactorial
inheritance, and low penetrance of susceptibility
alleles substantially complicate both study design and
interpretation of results. Notwithstanding these dif®-
culties, genome-wide scans for psoriasis susceptibility
have generated robust evidence for a major locus
lying within the major histocompatibility complex
(PSORS1, Psoriasis Susceptibility 1), on the short
arm of chromosome 6. Subsequent studies have
sought to re®ne the PSORS1 boundaries by means of
linkage disequilibrium ®ne mapping. Studies of pos-
itional candidate genes have also been undertaken,
focusing on HLA-C, corneodesmosin, and a-helix
coiled-coil rod homolog genes. Methodologic
approaches, results, and interpretations of these stud-
ies are discussed, as well as future research object-
ives. In particular, we emphasize the importance of
characterizing PSORS1 linkage disequilibrium pat-
terns and developing functional assays for disease-
associated alleles. Key words: a-helix coiled-coil rod
homolog/complex disease/corneodesmosin/HLA/linkage
disequilibrium. J Invest Dermatol 118:745±751, 2002
P
soriasis is a common in¯ammatory skin disorder affecting
approximately 2% of Caucasians. Though rarely fatal,
the disease is signi®cantly debilitating not least when
complicated by the occurrence of a sero-negative,
potentially disabling arthritis, as seen in some 5% of
psoriasis patients (Christophers and Sterry, 1993). Psoriasis is
associated with keratinocyte hyperproliferation and dermal in®ltra-
tion of activated T lymphocytes (Barker, 1991), yet the underlying
pathogenic mechanisms remain poorly characterized.
A signi®cant genetic component to psoriasis susceptibility has
long been supported by observations of family disease clustering,
elevated concordance rates amongst monozygous twins, and
numerous reports of disease association with the HLA-Cw6
antigen (Elder et al, 1994). These data were mostly derived using
patients presenting at a young age (< 40 y), leading to the
suggestion that HLA-Cw6 predisposes to an earlier onset of
psoriasis (Enerback et al, 1997).
Over the last few years, a number of research groups have
pursued major studies investigating the molecular genetic basis of
psoriasis. It therefore seems timely to review the current state of
psoriasis genetics research. Particular attention is given to the
genetic analysis of the major histocompatibility complex (MHC) on
human chromosome 6, a region subject to intense scrutiny, as
evidenced by the rush of recent publications (Asumalahti et al,
2000; Nair et al, 2000; Chia et al, 2001; O'Brien et al, 2001).
SOME KEY METHODOLOGIC CONSIDERATIONS
Psoriasis is etiologically a complex disorder with a widely held view
that environmental factors trigger the disease in genetically
susceptible individuals. Such multifactorial pathways are considered
likely to underlie the majority of common medical disorders
including in¯ammatory bowel disease, asthma, or diabetes.
Re¯ecting the major public health concerns attributed to these
common disease states and the need to better understand their
pathogenesis, considerable effort has been exerted to characterize
associated molecular genetic determinants. Signi®cant break-
throughs have recently been achieved, e.g., the identi®cation of
the NOD2 and CAPN10 genes as contributors to susceptibility for
Crohn's disease and type II diabetes, respectively (Horikawa et al,
2000; Hugot et al, 2001; Ogura et al, 2001). It is clear, however,
that the identi®cation of common disease susceptibility genes
remains a major challenge. Some of the recognized dif®culties are
brie¯y discussed below. Detailed reviews providing greater insight
into such methodologic issues have recently been published
elsewhere (Terwilliger and Weiss, 1999; Risch, 2000).
Linkage analysis Linkage analysis of extended pedigrees has
proven a most effective tool for the assignment of loci involved in
monogenic disorders. The ef®ciency of such mapping strategies is
critically dependent upon correct assumptions regarding the disease
mode of inheritance. As the transmission of complex traits does not
follow simple Mendelian inheritance patterns, novel linkage tools
have been devised. These statistics typically implement
``nonparametric'' linkage analysis strategies, which highlight
regions of the genome that demonstrate excess of allele sharing
between affected family members (Risch, 2000).
Further compounding factors need to be considered.
Susceptibility to complex disorders is probably determined by the
interplay between several independent genes, such that detecting
the effect of a single locus requires due care in study design.
Usually, large family cohorts have to be recruited, capable of
Manuscript received August 30, 2001; revised January 8, 2002; accepted
for publication January 14, 2002.
Reprint requests to: Professor Richard Trembath, Division of Medical
Genetics, Adrian Building, University Road, Leicester LE1 7RH, U.K.
Email: rtrembat@hgmp.mrc.ac.uk
Abbreviations: CDSN, corneodesmosin; HCR, a-helix coiled-coil rod
homolog; LD, linkage disequilibrium; SNP, single-nucleotide polymorph-
ism; TDT, transmission disequilibrium test.
0022-202X/02/$15.00 ´ Copyright # 2002 by The Society for Investigative Dermatology, Inc.
745
generating adequate power to declare linkage; in general, the
weaker the contribution of a single locus, the larger the sample size
needed to detect it. Recruiting large data sets raises issues of
phenotypic and genetic heterogeneity, however. Distinct genes
may contribute to disease susceptibility in different populations or
disease subtypes. Patient clinical phenotypes should therefore be
meticulously characterized, in order to minimize the introduction
of disease heterogeneity. Furthermore, many populations show a
remarkable degree of genetic admixture, re¯ecting a long history of
migration. The gene-¯ow underlying such admixed populations
can introduce multiple genetic determinants for a given trait,
thereby decreasing the power to detect linkage to a single locus
(Pfaff et al, 2001). Efforts to ascertain families from a similar ethnic
background may reduce the level of genetic admixture. A number
of investigators have described the theoretical advantages of this
approach (de la Chapelle and Wright, 1998) and several molecular
genetic studies have been performed on isolated populations. For
instance, an atopy susceptibility locus has recently been assigned
through the analysis of a Finnish cohort (Latinen et al, 2001). Even
carefully selected data sets may still present signi®cant heterogen-
eity, however, through undetected population strati®cation or the
occurrence of phenocopies (nongenetic examples of the disorder).
Failures to replicate reported linkage assignments should be
considered in the context of these confounding factors. Lack of
replication may re¯ect false positive linkage results. For example, a
linkage of schizophrenia to chromosome 5q could not be
replicated, despite the assignment being strongly supported by a
highly signi®cant LOD score. It was eventually agreed that the
original result represented a spurious assignment (McGuf®n et al,
1990). Alternatively, the inability to replicate previous ®ndings may
simply re¯ect locus heterogeneity, which substantially reduces the
power to detect linkage (Leal and Ott, 2000).
In psoriasis, independent genome-wide scans have suggested the
involvement of a large number of chromosomal regions (Table I),
but replication has only been achieved for a limited number.
Profoundly robust evidence supports the presence of a major
susceptibility locus (PSORS1) within the MHC, as linkage to this
region has been observed by many authors (Table I). The
assignment of other loci, such as PSORS2 and PSORS4, has
been replicated in independent studies. In contrast, involvement of
other genomic regions (e.g., chromosome 20p) has been suggested
in several studies, yet in none has genome-wide signi®cance been
achieved. Such regions may represent loci with minor effects
potentially requiring very large data sets to reveal their contribution
to disease susceptibility. Finally, it is noteworthy that four psoriasis
susceptibility loci, namely PSORS2, PSORS4, PSORS5, and the
chromosome 20p locus, overlap susceptibility regions for atopic
dermatitis (Fig 1) (Cookson et al, 2001). This observation suggests
the intriguing possibility that common genetic susceptibility
pathways underlie in¯ammatory skin disorders.
Association studies In complex diseases, genome-wide scans
typically assign susceptibility loci to broad genomic regions,
spanning 20 cM or more. Re®nement of these locations cannot
be achieved by the traditional crossover family-based analysis. In
multifactorial diseases, genetic heterogeneity and the low
penetrance of at-risk alleles each contribute to blur the
relationship between phenotype and single locus genotype.
Alternative approaches to susceptibility locus re®nement have
been proposed. These methods typically rely on linkage
disequilibrium (LD) ®ne mapping (Jorde, 1995). The rationale
for these experiments is the assumption that an ``at-risk allele'' arose
on an ancestral haplotype (a segment of DNA inherited from a
common ancestor), and then transmitted through a number of
generations to be inherited by patients under analysis (Fig 2). As
the ancestral haplotype will have been broken down by
recombination, a process occurring at each meiosis, only marker
alleles lying in close proximity to the ``true'' susceptibility locus will
continue to be coinherited and therefore can be found at increased
frequency among affected individuals. Based on this rather simple
model, the broad susceptibility regions identi®ed by genome-wide
scans may be re®ned by increasing the number of genetic markers
typed within a region, and allele frequencies compared between
patients and controls. LD is typically maintained across much
smaller genetic distances (typically less than 1 cM) than would be
detected in linkage studies in family-based analysis. The marker
alleles in LD with the disease will therefore highlight the most
likely location for the susceptibility gene.
Although potentially powerful, the LD mapping approach has
some recognized drawbacks. The results of case-control studies can
easily be biased through inappropriately matched controls and also
through undetected population strati®cation. Indeed, these short-
comings have been held responsible for the poor reproducibility
plaguing association studies of complex diseases (Altshuler et al,
2000). Moreover, the use of unrelated subjects does not allow the
construction of haplotypes, a powerful tool for mapping suscep-
tibility genes in complex traits (Rioux et al, 2001). Hence, in recent
years a number of family-based association tests have been
developed (Schaid, 1998), the most popular of which is the so-
called transmission disequilibrium test (TDT). The TDT requires
genotyping of nuclear families including at least an affected
offspring together with the parents. In the analysis of such trios,
parental alleles transmitted to the affected offspring are identi®ed
and scored as cases. Conversely the untransmitted parental alleles
are scored as controls. Allele frequencies are determined for the two
groups and the signi®cance of the difference is assessed by a c2 test
(Spielman et al, 1993).
So far, efforts to re®ne psoriasis susceptibility loci using LD
mapping strategies have focused on the PSORS1 region. The
results of these studies are reviewed below.
How large is the minimal PSORS1 region? The initial
approach to susceptibility locus ®ne mapping relied on the analysis
Table I. Published psoriasis susceptibility loci
Chromosomal location Locus name Linkage reports
1p PSORS7 Veal et al (2001)
1q PSORS4 Capon et al (1999a)
Bhalerao and Bowcock (1998)
2p Veal et al (2001)
Bhalerao and Bowcock (1998)
2q Trembath et al (1997)
3q PSORS5 Enlund et al (1999b)
Samuelsson et al (1999)
4q13 Bhalerao and Bowcock (1998)
Samuelsson et al (1999)
4q34 PSORS3 Matthews et al (1996)
6p21.3 PSORS1 Nair et al (1997)
Trembath et al (1997)
Burden et al (1998)
Capon et al (1999b)
Enlund et al (1999a)
Jenisch et al (1998)
Samuelsson et al (1999)
Veal et al (2001)
7 Veal et al (2001)
8q Trembath et al (1997)
14q Bhalerao and Bowcock (1998)
Veal et al (2001)
15 Samuelsson et al (1999)
16q Nair et al (1997)
17q25 PSORS2 Tomfohrde et al (1994)
Nair et al (1997)
Samuelsson et al (1999)
Enlund et al (1999a)
19p13 PSORS6 Lee et al (2000)
Veal et al (2001)
20p Nair et al (1997)
Trembath et al (1997)
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of HLA haplotypes. A study by Schmitt-Egenolf et al (1996)
demonstrated an association between psoriasis and the extended
haplotype (EH) 57.1, including Cw6, B57, DRB1*0701,
DQA1*0201, and DQB1*0303 alleles. This is consistent with the
results of previous serologic surveys reporting associations with class
I antigens HLA-B13 and HLA-B57, as well as class II antigens
HLA-DR4 and HLA-DR7 (Elder et al, 1994). The Schmitt-
Egenolf study, however, indicated that HLA-Cw6 and HLA-B57
are the alleles showing the most signi®cant association, leading the
authors to conclude that the susceptibility gene lies towards the
class I side of the EH57.1 haplotype. Similar results were also
obtained by Jenisch et al (1998), who demonstrated that the EH57.1
class I alleles were selectively retained among affected individuals.
Three papers concerning the LD analysis of the PSORS1 interval
have been published (Balendran et al, 1999; Oka et al, 1999; Nair et
al, 2000). All three groups observed extended regions of LD within
PSORS1; however, distinct statistical approaches were adopted in
the independent studies and somewhat differing conclusions were
drawn particularly with regard to the extent and location of the
minimal PSORS1 region.
Balendran et al (1999) examined a sample of 78 north European
families by typing 14 markers spanning the entire MHC.
Figure 2. Re®nement of a disease
susceptibility locus by ancestral haplotype
analysis. Upper panel: the assumption is made that
an at-risk allele originally arose on a single
chromosome carrying a determined haplotype. In
the following generations, the haplotype in
question is transmitted to patients, together with
the at-risk allele (left). As no single susceptibility
allele is suf®cient to trigger a multifactorial disease,
the at-risk variant and the surrounding haplotype
may also be found on some control chromosomes,
even though at a lower frequency (right, black bar
with black circle). At the same time, some
unaffected individuals will inherit chromosomes
that did not undergo the unique mutation event
generating the susceptibility allele, but still carry
the same haplotype (right, black bar without black
circle). Lower panel: as generations succeed, all
haplotypes are disrupted by recombination. The
ancestral haplotype carrying the susceptibility allele
is broken down too, so that only the portion
lying in close proximity of the at-risk variant can
be maintained. Thus, the extension of minimal
conserved ancestral haplotypes can be used to
support the re®nement of a disease susceptibility
locus.
Figure 1. The psoriasis susceptibility loci
overlapping with loci for other in¯ammatory
disorders. The approximate extent of the
mapped region is highlighted with a solid black
bar to the right-hand side of the banded
chromosome and the associated diseases are
de®ned in the text. The approximate locations of
the NOD2 (Crohn's disease gene), MHC genes,
and the epidermal differentiation complex genes
are denoted by a bracket to the left-hand side of
the banded chromosome and labeled accordingly.
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Genotypes were analyzed using a battery of linkage and association
based methods. Haplotypes were also derived and ancestral MHC
chromosomes were inferred. The results of the various test statistics
showed a convergent peak at the boundary between class III and
class I loci, and were consistent with a PSORS1 location between
tumor necrosis factor a and STG genes (Fig 3).
In their ®ne mapping study, Oka et al (1999) adopted a different
experimental design. They focused their attention on a much
smaller genomic region of just over a megabase (»1000 kb)
segment surrounding HLA-C. This interval, selected on the basis of
the association between psoriasis and HLA-Cw6, was saturated
with 11 markers that were typed in 76 affected and 132 controls.
Thus, a case-control rather than a family-based cohort was analyzed
in this study. The presence of association was assessed using two
different statistics: the c2 test and the analysis of deviation from
Hardy±Weinberg equilibrium. The resulting p-values peaked
within a 111 kb interval telomeric to HLA-C, whereas less
signi®cant association was maintained along a broader interval
(Fig 3).
Nair et al (2000) carried out a comprehensive analysis of the
MHC, by typing 62 markers in 478 psoriasis families. The authors
observed two conserved haplotypes (RH1 and RH2) separated by a
50 kb interval de®ned by markers M6S111 and M6S169. As RH1
only was present on all the identi®ed risk haplotypes, the authors
concluded that the PSORS1 location could be re®ned to the 60 kb
RH1 interval (Fig 3).
The results from the three ®ne mapping studies are summarized
in Fig 3, clearly showing that there is no overlap between the
published minimal intervals. All three re®ned regions may extend
farther than assumed by the investigators, however. In the
Balendran study, the critical susceptibility interval region was
mainly inferred from ancestral haplotype analysis, so that the re®ned
intervals reported in Fig 3 correspond to the minimal conserved
haplotypes observed by the authors. The PSORS1 susceptibility
gene does not necessarily lie within conserved haplotype regions,
however. Like all crossover-de®ned loci, the minimal PSORS1
interval is actually delimited by the position of the two nearest
recombining markers. If the re®ned interval is extended to include
the closest markers that are not conserved along the ancestral
haplotype, then the size of minimal regions increases.
The interpretation of the Oka study is more problematic as the
analysis of unrelated individuals did not allow haplotypes to be
derived. The authors assumed that PSORS1 lies in the region
where both statistics yielded signi®cant p-values, but signi®cance at
a single test is maintained for some distance, on both sides of such
interval.
With regard to the Nair study, only two markers separate the
RH1 and RH2 haplotypes. Taken together, this region extends
over a 170 kb conserved interval, closely corresponding to the peak
of LD identi®ed by the TDT. Double recombination events
around the M6S111 and M6S169 markers would be required to
account for the separation of RH1 and RH2. Given that the
authors report ®ve distinct haplotypes carrying both RH1 and
RH2, several such double recombinations would have to be
assumed. An alternative hypothesis suggests the existence of a single
RH haplotype carrying two microsatellite markers that have
undergone a CA slippage mutation (Timsit, 1999). This hypothesis
is consistent with the observation that the two most common risk
haplotypes share the same M6S169 alleles and carry M6S111 alleles
differing for a single CA repeat. Overall, this interpretation would
support a larger PSORS1 interval, extending to include the 50 kb
segment harbouring M6S111 and M6S169 (Fig 3).
If the extended regions are aligned, some overlap between the
various studies can be detected (Fig 3). Indeed the comparison
between the different minimal intervals points to a 100 kb segment
telomeric to HLA-C, including OTF3, TCF19, and a-helix
coiled-coil rod homolog (HCR) genes. Many issues related to the
re®nement methodology, however (e.g., reliability of some test
statistics), are still a matter of considerable debate among workers in
the ®eld. Thus, the 100 kb interval described above can only be
considered a provisional assignment, and candidate genes lying in its
proximity cannot be excluded only on the basis of their position.
CANDIDATE GENE ANALYSES
Investigations of PSORS1 candidate genes have been accumulating
at an increasing pace as the evidence for an MHC susceptibility
gene grew ever more robust. The ®rst and most extensively
investigated candidate was HLA-C. The association between
psoriasis and the HLA-Cw6 antigen has been observed in a wide
range of ethnic groups, and there is a general correlation between
Figure 3. Outcome of PSORS1 re®nement
studies. The position of known genes is reported
in the upper part of the ®gure. Black boxes in the
lower part indicate published minimal intervals.
Grey boxes have been added to illustrate how
much farther these regions may extend (see text
for details).
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the prevalence of the disease and that of Cw6 (Mallon et al, 1999).
On this basis, several groups have carried out HLA-C molecular
analyses in psoriasis families. These studies have repeatedly
indicated the HLA-Cw*0602 allele as the most signi®cant marker
for disease risk prediction (Tazi Ahnini et al, 1999; Asumalahti et al,
2000; Enerback et al, 2000). Three different Cw6-positive
haplotypes that are associated with psoriasis (Cw6-B57, Cw6-
B13, and Cw6-B37), however, have been described (Elder et al,
1994). These three haplotypes confer different disease risks (Jenisch
et al, 1998), and HLA-C seems to lie outside the most likely
PSORS1 interval (Fig 3). Taken together with the lack of a
characterized functional role in psoriasis, HLA-Cw6 is widely
assumed be a marker in LD with the PSORS1 gene rather than the
susceptibility allele itself (Allen et al, 1999; Asumalahti et al, 2000;
Nair et al, 2000).
A second, extensively investigated candidate is the corneodes-
mosin (CDSN) gene (OMIM *602593). CDSN lies 160 kb
telomeric to HLA-C (Fig 3) and codes for corneodesmosin, a
desmosomal protein involved in keratinocyte cohesion and
desquamation (Guerrin et al, 1998). Interestingly, a recent study
has demonstrated CDSN overexpression and altered distribution in
psoriatic epidermis (Allen et al, 2001). These are disease-speci®c
changes, as they have not been observed in other in¯ammatory skin
disorders such as atopic dermatitis and lichen planus (Allen et al,
2001).
The CDSN gene is remarkably polymorphic and a single-
nucleotide polymorphism (SNP) frequency of up to 1 each 100 bp
has been observed (Enerback et al, 2000). Most CDSN variants
have been tested for association, and several studies have reported
signi®cant p-values for a coding SNP that causes a Ser®Leu
substitution (Allen et al, 1999; Jenisch et al, 1999; Tazi Ahnini et al,
1999; Enerback et al, 2000). This association was not observed in
certain ethnic groups, however, including Japanese, Finnish, and
Spanish (Ishihara et al, 1996; Asumalahti et al, 2000; Gonzalez et al,
2000). These discrepancies might still be accounted for by allelic
heterogeneity, however. As CDSN polymorphism content is so
high, SNP haplotypes rather than single alleles are likely to
in¯uence the protein structure. In this context, the effect of a
variant such as the Ser®Leu substitution could be reinforced or
neutralized, depending on the alleles that are in LD with it, in each
population. In conclusion, CDSN still remains an attractive
candidate gene because of its function, its skin-speci®c expression
pattern, and its alterations in psoriatic epidermis. At this stage, a
functional study of the psoriasis-associated CDSN SNP is clearly
needed. In particular, in vivo or in vitro experiments are required in
order to investigate the effects of the Ser/Leu variant on protein
expression and localization.
A third candidate, the HCR gene, has lately been under intense
scrutiny. HCR (OMIM *605310) was ®rst identi®ed as a putative
structural component of skin-related tissues, as it presented
trichohyalin, myosin, and laminin homologies (Guilladeux et al,
1998). Asumalahti et al (2000) demonstrated that the gene is
ubiquitously expressed but is upregulated in psoriatic epidermis.
They also tested the HCR as a PSORS1 candidate by analysing 17
intragenic SNPs in a sample of Finnish origin. Their study disclosed
a signi®cant association between psoriasis and a two-SNP haplotype
bearing two Arg®Trp substitutions (HCR*Trp-Trp allele).
O'Brien et al (2001) subsequently analyzed HCR in a smaller
data set of Swedish origin. They replicated the association with the
*Trp-Trp allele and observed signi®cant p-values for six additional
SNPs, including a third Arg®Trp substitution. When they
strati®ed their results according to Cw*0602 presence, however,
association was maintained only for one silent polymorphism. On
the other hand, stratifying for HCR SNPs did not affect association
with Cw*0602. On this basis, the authors concluded that the
association with the *Trp-Trp allele was solely due to LD with
Cw*0602 and therefore had no pathologic relevance. It could be
argued that Cw*0602 is not an SNP but a haplotype, however, as
its sequence is de®ned by several nucleotide changes along the
HLA-C gene. So, data strati®ed according to Cw*0602 presence
may not be comparable to data strati®ed according to HCR single
SNPs.
A second report questioning HCR candidacy was published by
Chia et al (2001). The paper shows that the HCR *Trp-Trp allele
lies on most but not all the at-risk haplotypes identi®ed by Nair et al
(2000) in their PSORS1 re®nement study. In particular, a Cw8-
B65 haplotype is described that does not carry the associated *Trp-
Trp allele. The p-values that originally demonstrated the prefer-
ential transmission of the Cw8-B65 haplotype, however, are on the
threshold of statistical signi®cance (Nair et al, 2000), and even if the
Cw8-B65 haplotype contributes to psoriasis pathogenesis the
absence of the *Trp-Trp allele could still be accounted for by
allelic heterogeneity. Chia et al also disputed the HCR pathogenic
role based on the observation of a common nonrisk haplotype
carrying HLA-Cw7 and the *Trp-Trp allele. This ®nding can be
explained by low penetrance of the risk allele, however, a feature
already noted in other complex disease susceptibility genes (Reich
and Lander, 2001). Indeed, the effects of the *Trp-Trp allele could
be modulated by haplotype-speci®c SNPs, as hypothesized for
CDSN. In this context, it would be interesting to investigate
whether the nonrisk Cw7 haplotype also carries the additional
HCR risk SNPs identi®ed by O'Brien et al (2001). In conclusion,
the data generated so far do not allow the dismissal of HCR as a
PSORS1 candidate: the analysis of additional data sets and the
functional characterization of the *Trp-Trp allele are still needed,
in order to elucidate HCR contribution to psoriasis susceptibility.
Other genes lying in the proximity of HLA-C have been
analyzed, albeit less systematically. Gonzalez et al (2000) reported an
association with one allele of the OTF3 gene in the Spanish
population. The authors themselves acknowledge, however, that
OTF3 is a somewhat unlikely candidate for disease susceptibility, as
the gene encodes a transcriptional factor playing a major rule in
embryonic stem cells lineage commitment (Niwa et al, 2000).
Teraoka et al (2000) analyzed the TCF19 gene (Fig 3), coding for a
cell growth regulator, ubiquitously expressed in the G1±S phases of
the cell cycle. They identi®ed three SNPs and one deletion
polymorphism, but failed to observe any association.
Our group has recently been investigating SPR1 and SEEK1
genes (Fig 3). Direct sequencing of SPR1 failed to detect any high-
frequency SNP within this gene (Munro et al, unpublished
observations).
WHERE DO WE GO FROM HERE?
So far, none of the analyzed candidates seems to match the criteria
for a disease susceptibility gene (see below). The PSORS1 region
may contain as yet uncharacterized transcripts, e.g., the MHC
sequence annotation predicts three open reading frames in the
interval between HLA-C and OTF3 (Ensembl database of
annotated genomic sequences, http://www.ensembl.org).
Interestingly, these open reading frames match expressed sequence
tags that map to the same region. No gene has yet been
characterized, however. This may in part be due to the complexity
of the target genomic region, containing a large number of repeats
and retrovirus-like elements. On the other hand, these expressed
sequence tags may represent expressed pseudogenes. To date, few
susceptibility genes have been characterized; hence criteria for
declaring disease causality are mostly based on theoretical consid-
erations (Terwilliger and Weiss, 1999; Risch, 2000). For instance, it
is widely assumed that the genetic contribution to complex
disorders is due to relatively high frequency SNPs with subtle
effects on protein function (Chakravarti, 1999). This did not prove
to be the case for Crohn's disease, however, in which a low-
frequency frameshift mutation of the NOD2 gene has recently
been implicated in disease susceptibility (Hugot et al, 2001; Ogura
et al, 2001). Likewise, replication of association has long been
considered an essential requirement for susceptibility gene assign-
ment. This implies that the same alleles determine disease
susceptibility in distinct populations. The real picture is likely to
be more complex, however. For instance, it has been demonstrated
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that the CAPN10 haplotype1 involved in type II diabetes
susceptibility confers very different risks in different ethnic groups
(Horikawa et al, 2000). Another implicit assumption underlying
most association studies is that disease susceptibility is caused by a
single or a few closely linked SNPs. Again, this is not necessarily the
case. Variation in adjacent genes may underlie disease susceptibility,
as is the case with the IDDM superlocus lying within the MHC
(Lie et al, 1999). More generally, the effect of single SNPs may vary
according to the haplotype they reside on. Indeed this has proven
to be the case even for a ``simple'' monogenic disorder like cystic
®brosis, where CFTR mutation effects can be modulated by
intronic variants (Estivill, 1996). If similar mechanisms were active
in the PSORS1 region, identifying psoriasis susceptibility alleles by
association studies alone could prove a formidable task indeed.
Despite these dif®culties, susceptibility gene assignment may still
be achieved by assessing the functional relevance of disease-
associated SNPs. Indeed, demonstrating that a given SNP affects
gene expression levels or protein secondary structure is expected to
provide robust support for the involvement of a candidate gene.
This is likely to be particularly true for the PSORS1 locus. The
con¯icting interpretations of recent association ®ndings show how
genetic analysis may be close to its limit, suggesting that further
resolution cannot be achieved owing to LD conservation along the
MHC. Before genetic analysis is set aside, however, it will be
important to ensure that a near complete assessment of the ancestral
history of the numerous genetic variants within the PSORS1
region has been achieved. The MHC is unusual in the way
extended regions of LD have been maintained, probably re¯ecting
complex mechanisms that ensure such genomic regions remain
intact. The availability of a high-resolution genetic map of this
region allows the detailed characterization of highly localized ``hot
spots'' of recombination within the MHC with important impli-
cations for disease causality (Jeffreys et al, in press). These studies
will need to be assessed in the light of such analysis. Together with
the rich and ¯exible array of functional analysis techniques,
researchers have now at their disposal adequate tools to identify
the long-hunted-for PSORS1 gene.
Note added in proof: Asumalahti et al have recently reported the
analysis of HLA-C/HCR/CDSN risk haplotypes in ethnically
diverse data sets, con®rming highly signi®cant association of
psoriasis with HLA-CW*0602 and HCR*TRP-TRP alleles
(Hum Mol Genet 11:589±597, 2002).
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